Comparing the effects of paxlovid with azvudine in patients with COVID-19 after lung transplantation: a single-center, real-world study, bidirectional cohort study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300067709

Enrollment

Unknown

Registered

2023-01-18

Start date

2023-01-16

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Paxlovid treatment plan group:N/A

azvudine treatment plan group:N/A

Eligibility

Sex/Gender

All

Age

30 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Patients with confirmed COVID-19 and not receiving systematic treatment; 2. Patients with paxlovid or azvudine treatment indications in accordance with the diagnosis and treatment scheme for novel coronavirus (trial version 9); 3. Patients after lung transplantation; 4. Aged > 18 years; 5. Voluntary or authorized agent signs informed consent.

Exclusion criteria

Exclusion criteria: 1. No use of Azvudine or paxlovid antiviral drugs; 2. Patients who received anti COVID-19 drugs other than azvudine and paxlovid; 3. Diseases (eg: Malignant tumors, stroke, acute myocardial infarction)in the period of rapid deterioration and progress; 4. Have a severe mental illness or any condition, which in the opinion of the investigator, will compromise the safety of the participant.

Design outcomes

Primary

Measure	Time frame
14-day conversion rate;Length of hospitalization;mortality;	—

Secondary

Measure	Time frame
WHO clinical progress assessment;Severe rate;	—

Countries

China

Contacts

Public ContactLuo Fengming

West China Hospital, Sichuan University

luofengming@hotmail.com+86 18980601355

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026